Acute Myeloid Leukemia

All categories, Therapeutic Indication

Real-World Validation of Menin Inhibition in Acute Leukemia

Syndax presented interim real-world evidence from the ROAR study at EHA 2026 showing an 82% overall response rate and 64% CR/CRh rate among heavily pretreated patients with relapsed or refractory NPM1-mutated or KMT2A-rearranged acute…

admin
June 11, 2026

All categories, Therapeutic Indication

OPTI-AML Venetoclax Optimization

Blood Cancer United announced more than 50 ASCO and EHA 2026 abstracts, highlighted by an oral EHA presentation from the randomized Phase 2 OPTI-AML substudy evaluating reduced-duration venetoclax dosing with azacitidine in newly diagnosed…

admin
May 28, 2026

Real-World Validation of Menin Inhibition in Acute Leukemia

OPTI-AML Venetoclax Optimization

Weekly Market Insight